Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

19.07B

Market cap19.07B

Price-Earnings ratio

14.97

Price-Earnings ratio14.97

Dividend yield

—

Dividend yield—

Average volume

1.66M

Average volume1.66M

High today

$97.25

High today$97.25

Low today

$93.82

Low today$93.82

Open price

$95.79

Open price$95.79

Volume

534.43K

Volume534.43K

52 Week high

$112.29

52 Week high$112.29

52 Week low

$53.56

52 Week low$53.56

Stock Snapshot

Incyte(INCY) stock is priced at $95.82, giving the company a market capitalization of 19.07B. It carries a P/E multiple of 14.97.

As of 2026-03-09, Incyte(INCY) stock has fluctuated between $93.82 and $97.25. The current price stands at $95.82, placing the stock +2.1% above today's low and -1.5% off the high.

Incyte(INCY) shares are trading with a volume of 534.43K, against a daily average of 1.66M.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

INCY News

Simply Wall St 1d

Assessing Incyte Valuation After EC Approval Of Zynyz For Advanced Anal Cancer

Advertisement EC approval of Zynyz sets fresh context for Incyte’s stock story Incyte (INCY) just received European Commission approval for Zynyz, used with c...

TipRanks 3d

Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion

Incyte ( (INCY) ) just unveiled an announcement. On February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter to Incyte for it...

TipRanks 3d

Incyte announces European Commission approval of Zynyz

Incyte (INCY) “announced that the European Commission has approved Zynyz in combination with carboplatin and paclitaxel for the first-line treatment of adult pa...

Analyst ratings

46%

of 28 ratings

Buy

42.9%

Hold

46.4%

Sell

10.7%

More INCY News

Simply Wall St 3d

Incyte’s Cash Flow Gains Reshape Earnings Outlook And Capital Return Options

Incyte, ticker NasdaqGS:INCY, is reporting sustained revenue growth alongside an expansion in free cash flow margins. The company is also showing strong earnin...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.